经济观察网 基于公开信息，强生（JNJ.US）在2026年有以下值得关注的事件动态，这些事件可能影响 公司运营和市场表现： 业绩经营情况 2026年业绩展望：强生管理层在2026年1月公布的业绩预测显示，2026年运营销售额预计区间为995亿美 元至1005亿美元，调整后每股收益区间为11.43美元至11.63美元，均高于华尔街分析师普遍预期。增长 主要受益于创新药物如TREMFYA、DARZALEX、CARVYKTI等以及医疗科技新品推动。 近期事件 滑石产品诉讼进展：联邦法院针对强生滑石产品与卵巢癌关联的"风向标"审判（Bellwether Trial）预计 最快于2026年下半年启动，该诉讼涉及重大索赔，但公司表示产品安全且将积极应对。 骨科业务分拆计划：强生计划在18至24个月内（从2025年底计）将增长较慢的骨科业务从公司整体业务 中分离，以聚焦高增长领域，这是公司转型战略的一部分。 药品降价协议影响：作为与特朗普政府达成降价协议的16家制药公司之一，强生需消化"数亿美元"的药 品降价冲击，但管理层表示已将其纳入2026年业绩预期，并保持增长韧性。 以上内容基于公开资料整理，不构成投资建议。 ...

A jury in Pennsylvania state court on Friday awarded $250,000 to the family of a woman who sued Johnson & Johnson alleging its talc-based baby powder was to blame for her ovarian cancer, according to an attorney for plaintiffs in nationwide talc litigation against the company.The jury in the Philadelphia Court of Common Pleas sided with family members of Gayle Emerson, who claimed that Johnson & Johnson knew for years its talc-based products were dangerous but failed to warn consumers, according to attorney ...

PHILADELPHIA--(BUSINESS WIRE)--A jury in the Philadelphia Court of Common Pleas has found Johnson & Johnson (NYSE:JNJ) responsible for the company's baby powder products contributing to the death of a Pennsylvania woman. The jury deliberated for more than three days before returning a verdict totaling $250,000 on behalf of the estate of York, Pennsylvania, resident Gayle Emerson, who died as a result of ovarian cancer in November of 2019 after filing her lawsuit six months earlier. The verd. ...

Key TakeawaysJohnson & Johnson (JNJ) was found liable by a Pennsylvania jury for a woman's ovarian cancer, resulting in a $250,000 damages award.Amazon (AMZN)-backed nuclear startup X-energy (via its subsidiary TRISO-X) received U.S. approval for its advanced reactor fuel, a critical step for its small modular reactor (SMR) deployment.UBS (UBS) analysts forecast a massive surge in corporate buybacks, expected to reach $30-50 billion per week through the end of March.Global oil benchmarks settled slightly hi ...

Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]A Johnson & Johnson banner is displayed on the front of the New York Stock Exchange (NYSE) in New York City, in New York City, U.S., December 5, 2023. REUTERS/Brendan McDermid [Purchase Licensing Rights, opens new tab]- Companies- Summary- Trial was second over ovarian cancer since J&J's latest bankruptcy ...

Johnson & Johnson (NYSE:JNJ) is among the most profitable mega cap stocks to buy. On February 6, Johnson & Johnson (NYSE:JNJ) disclosed 12-month pilot-phase data from the OMNY-AF study, which examined the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation (AFib). Announced during the 31st Annual AF Symposium in Boston, the results reveal that investigators achieved 100% acute procedural success with zero adverse events linked to the procedure. As stated by D ...

Johnson & Johnson (NYSE:JNJ) is one of the best medical research stocks to buy according to hedge funds. Johnson & Johnson (NYSE:JNJ) announced 12-month pilot-phase data from the OMNY-AF study on February 6 at the 31st Annual AF Symposium in Boston, evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation. It reported that the initial results for 12-month outcomes across the 30-patient pilot cohort reflect that investigators attained 100% acute proce ...

机构观点 2025年第四季度业绩超预期：Q4营收245.6亿美元，同比增长9.08%，调整后每股收益2.46美元，均高于 市场预期。创新药部门和医疗器械业务成为主要增长动力。管理层预计2026年营收区间为995亿至1005 亿美元，调整后每股收益指引为11.43至11.63美元，均高于华尔街预期，提振市场信心。 行业地位 强生以941.93亿美元营收蝉联2025年全球药企第一，肿瘤药物收入同比增长95.9%，凸显创新管线竞争 力。公司通过与美国政府的药品定价协议化解关税压力，首席财务官表示已消化"数亿美元"降价影响， 同时维持盈利增长韧性。 经济观察网强生(JNJ)股价在2026年2月12日表现强劲，但并未突破历史新高。收盘价为242.24美元，单 日上涨0.57%，盘中最高触及242.28美元，最低239.68美元。年初至今累计上涨17.05%，同期道琼斯指 数上涨4.3%，表现显著优于大盘。历史最高收盘价为2025年12月创下的约250美元水平，2月12日收盘 价未突破该高点。 业绩经营情况 截至2026年2月，28家机构中57%给予"买入"或"增持"评级，目标均价237.48美元，略低于当前股价，反 映 ...

Group 1 - The article provides a market analysis focusing on major indices such as Nasdaq 100 and S&P 500, along with specific companies like Johnson & Johnson and Meta Platforms Inc [1] - It highlights the performance trends of these indices and companies, indicating potential investment opportunities and market movements [1] Group 2 - The analysis includes detailed insights into the financial health and market positioning of Johnson & Johnson, emphasizing its recent earnings and strategic initiatives [1] - Meta Platforms Inc is discussed in terms of its market strategies and performance metrics, showcasing its impact on the tech sector [1]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 28, 2025 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number 1-3215 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 22-102 ...